Outcomes with Pre-Emptive Rituximab (pre-R) Treatment for Epstein-Barr Viremia (EBV) after Allogeneic Hematopoietic Stem Cell Transplantation (HCT)

被引：2
|
作者：
Jain, Tania
Kung, Shu Ting
Kosiorek, Heidi
Shah, Vishal
Khera, Nandita
Leis, Jose
Noel, Pierre
Palmer, Jeanne
Slack, James L.
Sproat, Lisa Z.
机构：
来源：
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | 2017年 / 23卷 / 03期
关键词：
D O I：
10.1016/j.bbmt.2016.12.187
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
382
引用
收藏
页码：S279 / S280
页数：2
相关论文
共 50 条
  • [21] Pre-Emptive Use of Rituximab in Epstein-Barr Virus Reactivation: Incidence, Predictive Factors, Monitoring, and Outcomes
    Papalexandri, Apostolia
    Gavriilaki, Eleni
    Vardi, Anna
    Kotsiou, Nikolaos
    Demosthenous, Christos
    Constantinou, Natassa
    Touloumenidou, Tasoula
    Zerva, Panagiota
    Kika, Fotini
    Iskas, Michalis
    Batsis, Ioannis
    Mallouri, Despina
    Yannaki, Evangelia
    Anagnostopoulos, Achilles
    Sakellari, Ioanna
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (22)
  • [22] Epstein-Barr virus-related disease after allogeneic HSCT and use of pre-emptive rituximab: clinical features and outcome
    Kinch, A.
    Hallbook, H.
    Arvidson, J.
    Sallstrom, K.
    Bondeson, K.
    Pauksens, K.
    BONE MARROW TRANSPLANTATION, 2017, 52 : S88 - S88
  • [23] Rituximab as pre-emptive therapy for EBV-reactivation following T-cell depleted allogeneic stem cell transplantation
    Peccatori, J
    Stanghellini, ML
    Bernardi, M
    Ruggeri, A
    Calbi, V
    Servida, P
    Rolla, S
    Racca, S
    Dominietto, A
    Tedone, E
    Soracco, M
    Bregni, M
    Ciceri, F
    Bacigalupo, A
    BONE MARROW TRANSPLANTATION, 2006, 37 : S165 - S165
  • [24] Pre-emptive therapy of CMV infection in allogeneic hematopoietic stem cell transplantation.
    Dentamaro, T
    Cudillo, L
    Picardi, A
    Postorino, M
    Gallone, D
    Masi, M
    Amadori, S
    BONE MARROW TRANSPLANTATION, 1999, 23 : S63 - S63
  • [25] Valganciclovir is safe and effective as pre-emptive treatment for CMV reactivation in allogeneic hematopoietic stem cell transplantation
    Pastano, R.
    Gigli, F.
    Andreola, G.
    Peccatori, F. A.
    Martinelli, G.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 468 - 468
  • [26] Pre-emptive treatment with rituximab efficiently prevents EBV lymphoproliferative disease (EBV-LPD) in paediatric allogeneic stem cell recipients
    Kalpoe, J
    van Tol, M
    Bredius, R
    van Baarle, D
    Annels, N
    Claas, E
    Kroes, A
    Lankester, A
    BONE MARROW TRANSPLANTATION, 2004, 33 : S192 - S193
  • [27] Early diagnosis and pre-emptive therapy of Epstein-Barr virus-associated lymphoproliferative disease following hematopoietic stem cell transplantation.
    Gruhn, B
    Meerbach, A
    Häfer, R
    Zell, R
    Berndt, A
    Kosmehl, H
    Wutzler, P
    Zintl, F
    BLOOD, 2001, 98 (11) : 393A - 394A
  • [28] Rituximab in the Treatment of Epstein-Barr Virus Infection after hematopoietic stem cell Transplantation in Children
    Peng, Zhiyong
    Li, Chunfu
    He, Yuelin
    BLOOD, 2014, 124 (21)
  • [29] Early detection of Epstein-Barr virus reactivation after allogeneic hematopoietic stem cell transplant and pre-emptive therapy with four courses of i.v. cydofovir
    Dominietto, A
    Tedone, E
    Soracco, M
    Bregante, S
    di Grazia, C
    Gualandi, F
    Lamparelli, T
    Raiola, AM
    van Lint, MT
    Frassoni, F
    Bacigalupo, A
    BONE MARROW TRANSPLANTATION, 2003, 31 : S91 - S91
  • [30] Pre-emptive therapy of Epstein-Barr virus (EBV) reactivation after allogeneic hematopoietic stem cell transplant (HSCT) with four courses of i.v. cydofovir: A single centre experience.
    Dominietto, A
    Tedone, E
    Soracco, M
    Bregante, S
    Di Grazia, C
    Lamparelli, T
    Raiola, AM
    Van Lint, MT
    Gualandi, F
    Frassoni, F
    Bacigalupo, A
    BLOOD, 2002, 100 (11) : 630A - 630A
12345